Jaimee L Heffner1, Kristin E Mull1, Jennifer B McClure2, Jonathan B Bricker1,3. 1. a Division of Public Health Sciences , Fred Hutchinson Cancer Research Center , Seattle , Washington , USA. 2. b Kaiser Permanente Washington Health Research Institute (formerly Group Health Research Institute) , Seattle , Washington , USA. 3. c Department of Psychology , University of Washington , Seattle , Washington , USA.
Abstract
BACKGROUND: Prior studies have suggested that, among the domains of depressive symptoms, low positive affect (PA) may have a distinct relationship with smoking cessation and relapse. However, the empirical basis for PA-focused interventions cessation is limited, with some mixed findings. OBJECTIVES: Using a large, diverse sample of treatment-seeking smokers, this study tested the hypothesis that PA adds unique predictive value beyond the effects of the other symptom domains in models of cessation and relapse. METHODS: Adult smokers participating in a smoking cessation trial (n = 450) were included in this post hoc analysis. Cessation outcomes included smoking abstinence at end of treatment and at 6-month follow-up. Relapse was defined as recurrence of smoking at 6-month follow-up among the end-of-treatment abstainers. Depressive symptoms were assessed at baseline using the Center for Epidemiologic Studies-Depression (CES-D) scale. RESULTS: With the exception of PA, all of the CES-D domains predicted reduced likelihood of smoking abstinence at end of treatment and cotinine-confirmed (but not self-reported) abstinence at 6 months, as did total CES-D score (all p-values < .05). None of the symptom domains predicted relapse. Conclusions/Importance: Our results provide further evidence that current depressive symptoms predict worse cessation outcomes, but they fail to support recent work suggesting that low PA has incremental predictive value for cessation or relapse beyond the other depressive symptom domains. To improve quit rates for smokers with depressive symptoms, evidence-based mood management interventions should be included in treatment planning.
BACKGROUND: Prior studies have suggested that, among the domains of depressive symptoms, low positive affect (PA) may have a distinct relationship with smoking cessation and relapse. However, the empirical basis for PA-focused interventions cessation is limited, with some mixed findings. OBJECTIVES: Using a large, diverse sample of treatment-seeking smokers, this study tested the hypothesis that PA adds unique predictive value beyond the effects of the other symptom domains in models of cessation and relapse. METHODS: Adult smokers participating in a smoking cessation trial (n = 450) were included in this post hoc analysis. Cessation outcomes included smoking abstinence at end of treatment and at 6-month follow-up. Relapse was defined as recurrence of smoking at 6-month follow-up among the end-of-treatment abstainers. Depressive symptoms were assessed at baseline using the Center for Epidemiologic Studies-Depression (CES-D) scale. RESULTS: With the exception of PA, all of the CES-D domains predicted reduced likelihood of smoking abstinence at end of treatment and cotinine-confirmed (but not self-reported) abstinence at 6 months, as did total CES-D score (all p-values < .05). None of the symptom domains predicted relapse. Conclusions/Importance: Our results provide further evidence that current depressive symptoms predict worse cessation outcomes, but they fail to support recent work suggesting that low PA has incremental predictive value for cessation or relapse beyond the other depressive symptom domains. To improve quit rates for smokers with depressive symptoms, evidence-based mood management interventions should be included in treatment planning.
Authors: Yessenia Castro; Miguel Ángel Cano; Michael S Businelle; Virmarie Correa-Fernández; Whitney L Heppner; Carlos A Mazas; David W Wetter Journal: Drug Alcohol Depend Date: 2014-01-31 Impact factor: 4.492
Authors: Megan E Piper; Stevens S Smith; Tanya R Schlam; Michael F Fleming; Amy A Bittrich; Jennifer L Brown; Cathlyn J Leitzke; Mark E Zehner; Michael C Fiore; Timothy B Baker Journal: J Consult Clin Psychol Date: 2010-02
Authors: Nelson A Morales; Michelle A Romano; K Michael Cummings; James R Marshall; Andrew J Hyland; Alan Hutson; Graham W Warren Journal: Cancer Causes Control Date: 2013-04-04 Impact factor: 2.506
Authors: Elias M Klemperer; John R Hughes; Catherine E Peasley-Miklus; Peter W Callas; Jessica W Cook; Joanna M Streck; Nicolas E Morley Journal: Nicotine Tob Res Date: 2021-01-22 Impact factor: 4.244
Authors: Noreen L Watson; Jaimee L Heffner; Kristin E Mull; Jennifer B McClure; Jonathan B Bricker Journal: Nicotine Tob Res Date: 2020-10-08 Impact factor: 4.244
Authors: Jaimee L Heffner; Kristin E Mull; Noreen L Watson; Jennifer B McClure; Jonathan B Bricker Journal: Drug Alcohol Depend Date: 2018-10-10 Impact factor: 4.492
Authors: Jaimee L Heffner; Megan M Kelly; Jeanette Waxmonsky; Kristin Mattocks; Edit Serfozo; Jonathan B Bricker; Kristin E Mull; Noreen L Watson; Michael Ostacher Journal: Nicotine Tob Res Date: 2020-08-24 Impact factor: 4.244
Authors: Christopher W Kahler; Anthony Surace; Rebecca E F Gordon; Patricia A Cioe; Nichea S Spillane; Acacia Parks; Beth C Bock; Richard A Brown Journal: Contemp Clin Trials Date: 2018-06-21 Impact factor: 2.226
Authors: Jaimee L Heffner; Noreen L Watson; Edit Serfozo; Kristin E Mull; Laura MacPherson; Melissa Gasser; Jonathan B Bricker Journal: JMIR Form Res Date: 2019-11-27
Authors: Elias M Klemperer; Robin Mermelstein; Timothy B Baker; John R Hughes; Michael C Fiore; Megan E Piper; Tanya R Schlam; Douglas E Jorenby; Linda M Collins; Jessica W Cook Journal: Nicotine Tob Res Date: 2020-08-24 Impact factor: 4.244